TMDX INVESTOR NOTICE: TransMedics Group, Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit

Core Viewpoint - TransMedics Group, Inc. is facing a class action lawsuit alleging violations of the Securities Exchange Act of 1934, with claims of misconduct including fraudulent practices and safety issues [1][3][4]. Group 1: Lawsuit Details - The class action lawsuit is titled Jewik v. TransMedics Group, Inc., and covers purchasers of TransMedics securities from February 28, 2023, to January 10, 2025 [1]. - Allegations include the use of kickbacks, fraudulent overbilling, and coercive tactics to generate revenue, as well as unsafe practices and lack of safety oversight [3]. - The lawsuit cites specific incidents, including a letter from U.S. Representative Paul Gosar accusing TransMedics of misconduct, which led to a decline in stock price [4]. Group 2: Impact on Stock Price - Following the allegations made by Scorpion Capital on January 10, 2025, regarding overbilling and providing rejected organs, TransMedics' stock price fell further [5]. Group 3: Legal Process - Investors who purchased TransMedics securities during the class period can seek appointment as lead plaintiff, representing the interests of the class [6]. - The lead plaintiff can choose a law firm to litigate the case, and participation as lead plaintiff does not affect the ability to share in any potential recovery [6]. Group 4: About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud cases, having recovered $6.6 billion for investors in class action cases [7]. - The firm has been recognized for securing the most monetary relief for investors and has a significant history of large recoveries in securities class action lawsuits [7].